{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:21:51Z","timestamp":1793308911256,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cgh.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T11:28:18Z","timestamp":1681903698000},"page":"2065-2075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Recent Advances in the Management of Primary Sclerosing Cholangitis"],"prefix":"10.1016","volume":"21","author":[{"given":"David N.","family":"Assis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.04.004_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis \u2013 a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib2","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study Group consensus process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109101","article-title":"Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC)","volume":"129","author":"Ringe","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cgh.2023.04.004_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.gastro.2003.07.011","article-title":"Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community","volume":"125","author":"Bambha","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.04.004_bib8","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/0016-5085(87)90618-4","article-title":"Improved survival with primary sclerosing cholangitis. A review of clinicopathological features and comparison of symptomatic and asymptomatic patients","volume":"92","author":"Helzberg","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis","volume":"38","author":"Broome","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.04.004_bib10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/lt.22161","article-title":"Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations","volume":"16","author":"Bowlus","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2023.04.004_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2017.10.028","article-title":"Primary sclerosing cholangitis is not rare among blacks in a multicenter North American consortium","volume":"16","author":"Goldberg","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2016.06.021","article-title":"Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease","volume":"151","author":"Lunder","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib13","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weism\u00fcller","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.dld.2018.06.024","article-title":"Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease","volume":"50","author":"Belle","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2023.04.004_bib16","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.29293","article-title":"Recommendations on the used of magnetic resonance imaging in PSC-a position statement from the International PSC Study Group","volume":"66","author":"Schramm","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2019.01.036","article-title":"Clinical utility of genomic analysis in adults with idiopathic liver disease","volume":"70","author":"Hakim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib20","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2015.06.008","article-title":"Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis","volume":"63","author":"De Vries","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.28963","article-title":"Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study","volume":"65","author":"De Vries","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib24","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cgh.2019.10.041","article-title":"Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis","volume":"18","author":"Eaton","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib26","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","volume":"19","author":"Trivedi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.51.4.562","article-title":"Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population","volume":"51","author":"Ponsioen","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.04.004_bib28","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","article-title":"Simple magnetic resonance scores associated with outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib29","article-title":"Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis","volume":"4","author":"Grigoriadis","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2023.04.004_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s41747-022-00312-x","article-title":"Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis","volume":"6","author":"Singh","year":"2022","journal-title":"Eur Radiol Exp"},{"key":"10.1016\/j.cgh.2023.04.004_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","article-title":"A\u00a0quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis","volume":"55","author":"Cristoferi","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2023.04.004_bib32","article-title":"Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis","volume":"4","author":"Cazzagon","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2023.04.004_bib33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A\u00a0revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cgh.2023.04.004_bib34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib35","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A\u00a0novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"De Vries","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.04.004_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, clinical utility, and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis","volume":"71","author":"Goet","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib37","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib38","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hep.31393","article-title":"The sclerosing cholangitis outcomes in pediatrics (SCOPE) index: a prognostic tool for children","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/hep.30085","article-title":"Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes of the disease: a derivation and validation study using machine learning","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2019.08.013","article-title":"Risk stratification in primary sclerosing cholangitis: it\u2019s time to move on from replicating imperfection and break the glass ceiling","volume":"71","author":"Trivedi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.04.004_bib42","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib43","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib44","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","article-title":"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis","volume":"34","author":"Imam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.04.004_bib45","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.04.004_bib47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib49","first-page":"246","article-title":"Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis","volume":"15","author":"Hilscher","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2023.04.004_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement in serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib52","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep4.1251","article-title":"Gamma glutamyltransferase reduction is associated with favorable outcomes in pediatric primary sclerosing cholangitis","volume":"2","author":"Deneau","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2023.04.004_bib53","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cgh.2023.04.004_bib54","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis \u2013 a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.04.004_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A\u00a0triple blinded, randomized placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J\u00a0Gastrointest Liver Dis"},{"key":"10.1016\/j.cgh.2023.04.004_bib56","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20943","article-title":"Novel biotransformation and physiological properties of norursodeoxycholic acid in humans","volume":"42","author":"Hofmann","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib61","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000454904","article-title":"Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases","volume":"35","author":"Halibasic","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2023.04.004_bib62","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","article-title":"24-norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation","volume":"75","author":"Zhu","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"Norursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib65","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.04.004_bib66","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cpt.1930","article-title":"Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol","volume":"108","author":"Ghonem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.04.004_bib67","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep4.1787","article-title":"Adjunct fenofibrate up-regulates bile acid glucuronidation and improves treatment response for patients with cholestasis","volume":"5","author":"Gallucci","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2023.04.004_bib68","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cgh.2023.04.004_bib69","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jhbp.281","article-title":"Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis","volume":"22","author":"Mizuno","year":"2015","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.cgh.2023.04.004_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.984","article-title":"Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Hatami","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.cgh.2023.04.004_bib71","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.crohns.2012.09.016","article-title":"Efficacy, safety and tolerability of vidulfudimus in patients with inflammatory bowel disease: the ENTRANCE study","volume":"7","author":"Herrlinger","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.04.004_bib72","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/hep4.1926","article-title":"A\u00a0pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis","volume":"6","author":"Carey","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2023.04.004_bib73","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib74","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib75","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1055\/s-0032-1325677","article-title":"Risk factors for complications of ERCP in primary sclerosing cholangitis","volume":"44","author":"Ismail","year":"2012","journal-title":"Endoscopy"},{"key":"10.1016\/j.cgh.2023.04.004_bib76","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.cgh.2022.09.006","article-title":"Bile duct colonization with Enterococcus sp. associated with disease progression in primary sclerosing cholangitis","volume":"21","author":"Zigmond","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib77","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","article-title":"No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis","volume":"155","author":"Ponsioen","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib78","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1055\/s-0043-107029","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) clinical guideline","volume":"49","author":"Aabakken","year":"2017","journal-title":"Endoscopy"},{"key":"10.1016\/j.cgh.2023.04.004_bib79","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib80","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/hep.31575","article-title":"Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis","volume":"73","author":"Eaton","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.004_bib81","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2022.11.011","article-title":"Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis","volume":"78","author":"Villard","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.004_bib82","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2015.08.046","article-title":"An optimized set of fluorescence in situ hybridization probes for detection of pancreaticobiliary tract cancer in cytology brush samples","volume":"149","author":"Fritcher Barr","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.004_bib83","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/ajg.2011.272","article-title":"Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma","volume":"106","author":"Fritcher Barr","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.04.004_bib84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/path.5994","article-title":"Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis","volume":"258","author":"Kamp","year":"2022","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.cgh.2023.04.004_bib85","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.gie.2022.10.014","article-title":"Next generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis","volume":"97","author":"Kamp","year":"2022","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2023.04.004_bib86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/cncy.22528","article-title":"Next-generation sequencing in the evaluation of biliary strictures in patients with primary sclerosing cholangitis","volume":"130","author":"Scheid","year":"2022","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.cgh.2023.04.004_bib90","series-title":"Organ procurement and transplantation network","article-title":"Briefing to the OPTN Board of Directors on updating National Liver Review Board Guidance and Policy Clarification","year":"2021"},{"key":"10.1016\/j.cgh.2023.04.004_bib87","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/lt.24496","article-title":"Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: comparison of risk factors between living and deceased donor recipients","volume":"22","author":"Gordon","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2023.04.004_bib88","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ajt.16864","article-title":"Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: experience from the European liver transplant registry","volume":"22","author":"Heinemann","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cgh.2023.04.004_bib89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/lt.21394","article-title":"Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation","volume":"14","author":"Alexander","year":"2008","journal-title":"Liver Transpl"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652300277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652300277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:45Z","timestamp":1761543825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652300277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S154235652300277X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.04.004","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in the Management of Primary Sclerosing Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}